BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 16757414)

  • 1. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
    Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
    Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
    Brown JJ; Ramalingam L; Zacharin MR
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Osteonecrosis of the jaw associated with the use of bisphosphonates in multiple myeloma: report of four cases and literature review].
    Li LH; Wu XB; Chen WM; Chen JX; Wu Y; Chen SL
    Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2986-7. PubMed ID: 19080077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
    Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
    Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural history of osteonecrosis of the jaw in patients with multiple myeloma.
    Badros A; Terpos E; Katodritou E; Goloubeva O; Kastritis E; Verrou E; Zervas K; Baer MR; Meiller T; Dimopoulos MA
    J Clin Oncol; 2008 Dec; 26(36):5904-9. PubMed ID: 19018084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates and jaw osteonecrosis: the UAMS experience.
    Clarke BM; Boyette J; Vural E; Suen JY; Anaissie EJ; Stack BC
    Otolaryngol Head Neck Surg; 2007 Mar; 136(3):396-400. PubMed ID: 17321866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
    García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
    Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
    Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
    J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.
    Fehm T; Beck V; Banys M; Lipp HP; Hairass M; Reinert S; Solomayer EF; Wallwiener D; Krimmel M
    Gynecol Oncol; 2009 Mar; 112(3):605-9. PubMed ID: 19136147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.
    Kraj M; Pogłód R; Maj S; Owczarska K
    Acta Pol Pharm; 2006; 63(5):450-2. PubMed ID: 17357613
    [No Abstract]   [Full Text] [Related]  

  • 13. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.
    Ortega C; Montemurro F; Faggiuolo R; Vormola R; Nanni D; Goia F; Gilardino MO; Aglietta M
    Acta Oncol; 2007; 46(5):664-8. PubMed ID: 17562443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.
    Corso A; Varettoni M; Zappasodi P; Klersy C; Mangiacavalli S; Pica G; Lazzarino M
    Leukemia; 2007 Jul; 21(7):1545-8. PubMed ID: 17410188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.
    Berenson JR; Yellin O; Crowley J; Makary A; Gravenor DS; Yang HH; Upadhyaya GH; Flinn IW; Staszewski H; Tiffany NM; Sanani S; Farber CM; Morganstein N; Bolejack V; Nassir Y; Hilger JD; Sefaradi A; Shamouelian A; Swift RA
    Am J Hematol; 2011 Jan; 86(1):25-30. PubMed ID: 21120861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
    Abu-Id MH; Warnke PH; Gottschalk J; Springer I; Wiltfang J; Acil Y; Russo PA; Kreusch T
    J Craniomaxillofac Surg; 2008 Mar; 36(2):95-103. PubMed ID: 18234504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases.
    Bagan JV; Murillo J; Jimenez Y; Poveda R; Milian MA; Sanchis JM; Silvestre FJ; Scully C
    J Oral Pathol Med; 2005 Feb; 34(2):120-3. PubMed ID: 15641993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the jaw: who gets it, and why?
    Reid IR
    Bone; 2009 Jan; 44(1):4-10. PubMed ID: 18948230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
    Estilo CL; Van Poznak CH; Wiliams T; Bohle GC; Lwin PT; Zhou Q; Riedel ER; Carlson DL; Schoder H; Farooki A; Fornier M; Halpern JL; Tunick SJ; Huryn JM
    Oncologist; 2008 Aug; 13(8):911-20. PubMed ID: 18695259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells.
    Allegra A; Oteri G; Nastro E; Alonci A; Bellomo G; Del Fabro V; Quartarone E; Alati C; De Ponte FS; Cicciù D; Musolino C
    Hematol Oncol; 2007 Dec; 25(4):164-9. PubMed ID: 17577204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.